Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2026-06-26 16:30:03 ET · period of report 2026-06-25 · accession 0001193125-26-285558 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-26 16:30 | 2026-06-25 | DFTX | Wiley Matthew T. | Chief Commercial Off | S - Sale | $45.03 | -2,867 | 174.6K | -2% | -$129.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-06-25 | S | D | 2,867 | $45.03 | 174,633 | D | — | — | (F1) Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2025. |